Medincell stock declines 3.5%, among the steepest falls in the SBF 120
The Montpellier-based biopharmaceutical company is giving back part of the previous day's rebound, despite a well-oriented Paris market. The stock remains clearly established above its moving averages, following an eventful early October marked by U.S. approval of an olanzapine formulation developed with Teva.
A decline at odds with the SBF 120, following the surge linked to U.S. approval
At €26.22, Medincell is down 3.67% during the session, while the SBF 120 is up 0.51%. The stock is among the index's steepest decliners, ranking at the bottom of the index. This pullback moderates an October that remains very favorable, with a gain of 20.5% over the month, driven by FDA approval of Weltruza, announced on October 9, which opens the door to up to $112 million in milestone payments. Over one week, the performance is -1.35%, a sign that consolidation continues from this peak.
Moving averages at €25.25 and €24.13 frame the stock despite profit-taking
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price remains above its 20-day MA at €25.25 (a gap of 3.84%) and its 50-day MA at €24.13 (8.66%), which limits the scope of today's decline. The RSI at 59 is neutral: it has not tipped into overbought territory despite the month's gains. On the financing side, Medincell has also obtained a new non-dilutive loan of €13.8 million, bringing the funds secured since July to €41.8 million. For technical reference points, support is found at €21.40 and resistance at €29.06.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T4 2025
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
